One year into Dyne Therapeutics’ Phase 1/2 ACHIEVE trial, zeleciment basivarsen (z-basivarsen) produced a 4.8% improvement in Quantitative Muscle Testing total and hand grip scores relative to baseline in a pooled dose group of adults with myotonic dystrophy type 1. That number matters because DM1 is a disease where patients typically lose function over time, not gain it, and a gain at twelve months in a dose-finding study is the kind of signal that shapes whether a company moves to a registrational design.
The data come from the multiple ascending dose portion of ACHIEVE, a randomized, placebo-controlled, double-blind study enrolling adults aged 18 to 49. Dyne disclosed the one-year readout in an 8-K filed September 29, 2026, alongside a press release and investor presentation. The trial had already reported six-month functional data; the twelve-month cut extends the durability picture and is the latest test of whether the FORCE platform, which couples an antibody fragment targeting transferrin receptor 1 on muscle cells to the oligonucleotide payload, translates its delivery mechanism into clinical benefit.
DM1 is managed largely with off-label approaches, and approved options in the disease remain limited, which puts particular weight on Phase 1/2 functional readouts as early evidence that a drug does anything useful before the company commits to a larger trial. The QMT signal at one year is encouraging, but the MAD cohort in a Phase 1/2 study is small by design, and pooled-dose analyses can obscure dose-response relationships that matter for choosing the right regimen in a Phase 3.
The number to watch next is whether Dyne reports a dose-specific breakdown alongside the pooled figure, and how the safety profile from the full twelve-month exposure compares to the earlier six-month data. If tolerability holds across the longer observation window, that gives the company a cleaner path to selecting a dose for a pivotal design.
Source link: https://www.sec.gov/Archives/edgar/data/1818794/000181879426000009/dyn-20260929.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
